Fig. 3: GALNT7 levels remain high in castrate resistant prostate cancer.
From: Upregulation of GALNT7 in prostate cancer modifies O-glycosylation and promotes tumour growth
Analysis of GALNT7 protein levels across two prostate cancer tissue microarrays (TMAs) using immunohistochemistry and in serum samples using sandwich ELISA assays. A Immunohistrochemistry analysis of GALNT7 levels in a previously published TMA [26]. GALNT7 levels in tumour tissue are significantly reduced after neoadjuvant hormonal therapy (NHT) (n = 162, unpaired t test, p < 0.0001). Scale bar is 100 µm. B Analysis of a 125 case TMA reveals the levels of GALNT7 in hormone naïve and castrate resistant prostate cancer (CRPC) are similar. Scale bar is 100 µm. C GALNT7 serum levels significantly decrease following ADT (n = 20, Mann Whitney U test, p = 0.0039). D The serum levels of GALNT7 in men with mCRPC are significantly higher than in men with hormone naïve prostate cancer (n = 260, unpaired t test, p < 0.001). E In the SU2C mCRPC patient cohort (n = 163) [33, 80] GALNT7 mRNA levels correlate with the androgen response pathway (NES 2.45; FDR q value = <0.001).
